CRDL — Cardiol Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1702123 ·
Last close
$1.86
Market Cap
$217.29M
52W High
$2.00
52W Low
$0.96
ADV30
1,210,258
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,706,794 | -10,818,589 | 31,406,607 | 27,673,191 | 7,203,302 |
| Dec 2025 | 0 | — | -8,030,975 | -7,212,569 | 23,619,933 | 21,416,684 | 5,742,215 |
| Sep 2025 | 0 | — | -10,180,100 | -9,964,281 | 12,947,801 | 11,622,408 | 3,386,926 |
| Jun 2025 | 0 | — | -7,676,158 | -8,354,371 | 19,937,699 | 18,195,052 | 8,129,824 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,218,514
Investing CF
$-60,130
Financing CF
$29,153,456
CapEx
$-60,130
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.42
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-223,891,564
Inventory
—
Receivables
$339,706
ST Investments
—
EBIT TTM
$-35,594,027
Pretax Income TTM
$-36,349,810
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -34,316,296 | -33,818,874 | 23,619,933 | 5,742,215 | — | -23,854,650 |
| Dec 2024 | 0 | -40,276,651 | -36,677,299 | 31,863,751 | 7,135,268 | — | -25,060,867 |
| Dec 2023 | 0 | -29,785,504 | -28,128,292 | 36,700,508 | 8,454,001 | — | -25,180,441 |
| Dec 2022 | 0 | -41,335,878 | -30,930,647 | 62,028,518 | 9,826,930 | — | -27,220,345 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.22
Max Pain — expiry 2026-09-18
max pain strike: $2.50 · spot: $1.86 · call oi: 1,011 · put oi: 7
Expected Move to 2026-09-18:
±$1.28
(68.82%) —
implied range
$0.58 –
$3.14
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACOG | Alpha Cognition Inc. | $212.33M | $9.75 | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $222.38M | $3.08 | — |
| VYGR | Voyager Therapeutics, Inc. | $211.97M | $3.44 | — |
| CHRS | Coherus Oncology, Inc. | $210.12M | $1.36 | — |
| TARA | Protara Therapeutics, Inc. | $228.70M | $3.87 | — |
News headlines (Yahoo Finance, 1h cache)
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?
2026-08-24 16:00 · Yahoo
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial
2026-08-12 12:01 · Yahoo
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
2026-08-05 11:27 · Yahoo
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association
2026-07-14 11:27 · Yahoo
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
2026-07-09 11:27 · Yahoo
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
2026-06-25 11:27 · Yahoo
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
2026-06-23 11:27 · Yahoo
Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
2026-05-15 16:22 · Yahoo
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
2026-05-14 11:27 · Yahoo
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
2026-05-07 11:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.